Genetically Modified Cell Lines / Isogenic Cell Lines
Isogenic Cell Lines for Drug Dicovery: Isogenic cell lines represent a unique toolset for studying the impact of genotype on cellular phenotype.
Isogenic Cell Lines for Drug Dicovery: Isogenic cell lines represent a unique toolset for studying the impact of genotype on cellular phenotype. An isogenic cell line is a cell line that has been engineered from a parental line through the introduction of a targeted gene mutation. In doing so, the parental cell line inherently becomes a control line to which the engineered line can be referenced. Isogenic cell line pairs can be incredibly useful as tools for studying cellular biology, such as the impact of genotype on cellular phenotype, as well as for parallel, high throughput screening to enable the discovery of therapeutic compounds that exhibit genotype-specific toxicity. Applied StemCell offers a number of homozygous isogenic cell lines.
For genome engineering applications, we also offer cell lines that have been modified to enable more efficient genome editing, such as our Cas9-expressing Jurkat line, and hiPSC TARGATT™ Master line.
In addition to our off-the-shelf products, we offers custom cell line engineering services for the generation of knock-out, point mutation, knock-in, inducible, and reporter cell lines.
Cell Lines expressing the CRISPR Cas9 nuclease enable you to carry out CRISPR genome editing applications including cell based assays and drug discovery.
Isogenic human disease models are a family of cells that are selected or engineered to accurately model the genetics of a specific patient population, in vitro. They are available with a genetically matched 'normal cell' to provide an isogenic system to research disease biology and novel therapeutic agents. They can be used to model any disease with a genetic foundation. Cancer is one such disease for which isogenic human disease cell line models have been widely used.1 The ONCOREF™ Isogenic engineered cell line products feature diverse oncogenic driver mutations in various pathways, including the MAPK and mTOR interactive signaling pathways.